Yahoo Finance

Jay Venkatesan Is The President of Angion Biomedica Corp. (NASDAQ:ANGN) And They Just Picked Up 5.7% More Shares

In fact, the recent purchase by President Jay Venkatesan was not their only acquisition of Angion Biomedica shares this year. They previously made an even bigger purchase of US$730k worth of shares at ...
Yahoo Finance

Angion to Participate in Upcoming Investment Conference

A webcast of the fireside chat will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir ...
Nasdaq

Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function

UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion’s ANG-3777 did not ...
Nasdaq

Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021

ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases ...
Business Wire

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion’s AKI-002-15 ...
Investing

Angion Biomedica Stock Price History

Explore the Angion Biomedica stock price history with detailed daily historical prices, including open, high, low, close, and volume data. Review past trends, identify key price levels, and find the ...
Yahoo

Switzerland's Vifor strikes kidney drug deal with Angion

Add Yahoo as a preferred source to see more of our stories on Google. ZURICH (Reuters) - Swiss drugmaker Vifor Pharma on Monday agreed to pay United States-based Angion Biomedica up to $80 million for ...
MedCity News

Cancer Biotech Elicio Finds Path to Public Markets Via Angion Reverse Merger

Cancer immunotherapy developer Elicio Therapeutics is finally getting a listing on the public markets to finance its clinical research. But rather than the traditional IPO it had been seeking, the ...
FierceBiotech

Angion hangs up 'for sale' sign, stops drug development work after flops force search for exit

For sale: one biotech, badly damaged. So starts what could be the final chapter in the story of Angion Biomedica. Weeks after halting a study over a potential safety signal, the biotech has decided to ...
Reuters

Angion Initiates Phase 2 Clinical Trial Of Ang-3777 In Patients With Acute Lung Injury Associated With Covid-19 Pneumonia

category Users of Meta's Facebook, Instagram report suffering some outages Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
pharmaphorum

Angion stock falls after agreeing Elicio Therapeutics merger

Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech ...
Business Wire

Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the ...